Shoehorning Living Cures into Dead Supply Chains | Hedley Rees

What happens when the biopharmaceutical industry tries to force living, hyper-perishable cell therapies into a legacy supply chain built for shelf-stable small molecules?

The entire system breaks down.

In this episode of Out of the Lab, host Nico sits down with Hedley Rees, Managing Director of PharmaFlow and a 40-year biopharma supply chain veteran, to pull back the curtain on why advanced therapies are hitting an operational dead end. Hedley details the immense logistical dangers of circular, "vein-to-vein" CAR-T workflows, the vulnerabilities left unaddressed by major wholesale distributors, and why the current industry model is built entirely on a structural paradox.

We pull apart:

• The Evolution of Tech Friction: Why modern manufacturing architectures were never truly re-engineered to survive deep cryogenic and cold chain realities.
  

• The 99% Attrition Trap: How archaic patent laws incentivize companies to claim molecules before establishing repeatable, scalable manufacturing processes.
  

• Post-Contractual Moral Hazard: The commercial reality check of what happens when private-equity-backed CDMOs hold all the leverage, leaving asset owners to face regulatory scrutiny alone.
  

• Back to the Future: Leveraging the collaboration model of Penicillin to integrate clinicians and engineers directly back into early-stage drug development.

Timestamps & Chapters:

• 00:00 – Introduction: Discussing operational complexity in cell and gene therapy.

• 01:44 – Alka-Seltzer vs. Monoclonal Antibodies: The failure to re-engineer legacy logistics.

• 03:34 – CAR-T Realities: Demystifying the highly volatile, circular "vein-to-vein" supply chain.

• 07:07 – Handover Hazards: Real-time tracking, temperature excursions, and runway failures.

• 13:26 – The Penicillin Blueprint: Why the earliest breakthrough required process over molecule.

• 19:39 – Changing the Rules: Redesigning patent law to solve structural asset attrition.

• 29:46 – The CDMO Leverage Trap: Navigating post-contractual moral hazard on the floor.

• 46:15 – Shared Risk Alliances: The future of integrated manufacturing capability.